A phase II trial of a histamine antagonist (DPPE) and doxorubicin in metastatic breast cancer
نویسندگان
چکیده
منابع مشابه
Pegylated liposomal doxorubicin plus carboplatin in patients with metastatic breast cancer: a phase II study.
BACKGROUND We determined the objective response rates produced by pegylated liposomal doxorubicin (PLD) plus carboplatin with/without trastuzumab (Herceptin). PATIENTS AND METHODS Patients with measurable disease were stratified by taxane treatment history and human epidermal growth factor receptor-2 status. TREATMENT PLD 30 mg/m(2) followed by carboplatin, day 1 of each 28-day cycle; human...
متن کاملLong-survival in responding patients with metastatic breast cancer treated with doxorubicin-docetaxel combination. A multicentre phase II trial.
BACKGROUND The doxorubicin-docetaxel combination is active in breast cancer; the aim of the present study was to evaluate the complete response rate and safety profile of the doxorubicin and docetaxel regimen as first-line chemotherapy in metastatic breast cancer patients. PATIENTS AND METHODS Forty-three patients entered the study. Treatment plan was: doxorubicin (50 mg/m2, i.v. bolus) follo...
متن کاملA phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer.
This phase II trial was conducted to evaluate the percentage of objective responses and the toxicity profile of combination doxorubicin (Adriamycin) and paclitaxel (Taxol) with granulocyte colony-stimulating factor as first-line therapy for patients with metastatic breast cancer (MBC) not previously exposed to anthracycline-containing regimens. Patients with measurable, visceral-dominant MBC an...
متن کاملPhase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer.
BACKGROUND Based on preclinical studies and a phase I trial of the combination of bortezomib and pegylated liposomal doxorubicin (PLD), which both showed activity in breast cancer, we conducted a phase II study of this regimen in patients with metastatic breast cancer. PATIENTS AND METHODS Patients received bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 of an every-21-day cycle, along with PLD ...
متن کاملAn unusual metastatic breast cancer presentation Report of a case
ABSTRACTWe are reporting a 43-year-old female breast cancer case with a solitary metastatic adenocarcinoma in clivus. This patient with a stage II (T1N1M0) breast cancer history has been followed for 7 years. Modified Radical Mastectomy (MRM) and 6 courses chemotherapy with CMF (Cyclophosphamide, Metotrexate, 5FU) regimen were done for her at the time of diagnosis. Also, she took tamoxifen tw...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Breast Cancer Research
سال: 1999
ISSN: 1465-542X
DOI: 10.1186/bcr-1999-66640